other material
confidence high
sentiment positive
materiality 0.85
DBV Technologies reports additional positive Phase 3 VITESSE data for VIASKIN Peanut Patch at AAAAI 2026
DBV Technologies S.A.
- 82.8% of treated children increased eliciting dose at month 12 vs ~48% placebo; 60.1% increased by ≥2 doses vs 23.4% placebo.
- 24% of placebo group decreased eliciting dose over 12 months vs 6.4% of treated group, indicating reduced sensitization.
- VIASKIN Peanut Patch was well tolerated; most adverse events were mild local application site reactions.
- Company plans to submit Biologics License Application (BLA) to FDA in the first half of 2026.
- All sensitivity analyses significant; response rate difference exceeded prespecified 15% threshold.